A Guanidine-Based Synthetic Compound Suppresses Angiogenesis via Inhibition of Acid Ceramidase

Sung Min Cho, Hyung Keun Lee, Qing Liu, Ming Wei Wang, Ho Jeong Kwon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Angiogenesis generates new blood vessels from pre-existing vessels. Tumors induce the formation of new blood vessels to ensure sufficient oxygen and nutrients for their growth. Normally, angiogenesis is induced by various pro-angiogenesis factors, including vascular endothelial growth factor (VEGF). Inhibition of VEGF is a promising approach to cancer treatment. A guanidine-based synthetic compound, E2, was identified as a potent hit from 68 guanidine-based derivatives by screening for angiogenesis inhibitors showing antiproliferative activity in human umbilical vein endothelial cells (HUVECs). To explore the mode of action of E2, target proteins were investigated using phage display biopanning, and acid ceramidase 1 (ASAH1) was identified as an E2-binding protein. Drug affinity responsive target stability (DARTS) and ASAH1 activity assays revealed the direct binding of E2 to ASAH1. Moreover, siRNA knockdown of ASAH1 demonstrated its role as an angiogenesis factor. Consequently, E2 inhibited chemoinvasion and tube formation of HUVECs in a dose-dependent manner. E2 also potently suppressed neo-vascularization of chorioallantoic membranes in vivo. Collectively, these data suggest that E2 is a novel angiogenesis inhibitor and ASAH1 is proposed to be a new antiangiogenesis target.

Original languageEnglish
Pages (from-to)11-19
Number of pages9
JournalACS Chemical Biology
Volume14
Issue number1
DOIs
Publication statusPublished - 2019 Jan 18

Fingerprint

Acid Ceramidase
Angiogenesis Inhibitors
Angiogenesis Inducing Agents
Guanidine
Endothelial cells
Human Umbilical Vein Endothelial Cells
Blood vessels
Vascular Endothelial Growth Factor A
Blood Vessels
Chorioallantoic Membrane
Bacteriophages
Oncology
Small Interfering RNA
Nutrients
Tumors
Assays
Neoplasms
Carrier Proteins
Screening
Display devices

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine

Cite this

Cho, Sung Min ; Lee, Hyung Keun ; Liu, Qing ; Wang, Ming Wei ; Kwon, Ho Jeong. / A Guanidine-Based Synthetic Compound Suppresses Angiogenesis via Inhibition of Acid Ceramidase. In: ACS Chemical Biology. 2019 ; Vol. 14, No. 1. pp. 11-19.
@article{ec2d2326be994e92a1d4e79826bccc3d,
title = "A Guanidine-Based Synthetic Compound Suppresses Angiogenesis via Inhibition of Acid Ceramidase",
abstract = "Angiogenesis generates new blood vessels from pre-existing vessels. Tumors induce the formation of new blood vessels to ensure sufficient oxygen and nutrients for their growth. Normally, angiogenesis is induced by various pro-angiogenesis factors, including vascular endothelial growth factor (VEGF). Inhibition of VEGF is a promising approach to cancer treatment. A guanidine-based synthetic compound, E2, was identified as a potent hit from 68 guanidine-based derivatives by screening for angiogenesis inhibitors showing antiproliferative activity in human umbilical vein endothelial cells (HUVECs). To explore the mode of action of E2, target proteins were investigated using phage display biopanning, and acid ceramidase 1 (ASAH1) was identified as an E2-binding protein. Drug affinity responsive target stability (DARTS) and ASAH1 activity assays revealed the direct binding of E2 to ASAH1. Moreover, siRNA knockdown of ASAH1 demonstrated its role as an angiogenesis factor. Consequently, E2 inhibited chemoinvasion and tube formation of HUVECs in a dose-dependent manner. E2 also potently suppressed neo-vascularization of chorioallantoic membranes in vivo. Collectively, these data suggest that E2 is a novel angiogenesis inhibitor and ASAH1 is proposed to be a new antiangiogenesis target.",
author = "Cho, {Sung Min} and Lee, {Hyung Keun} and Qing Liu and Wang, {Ming Wei} and Kwon, {Ho Jeong}",
year = "2019",
month = "1",
day = "18",
doi = "10.1021/acschembio.8b00558",
language = "English",
volume = "14",
pages = "11--19",
journal = "ACS Chemical Biology",
issn = "1554-8929",
publisher = "American Chemical Society",
number = "1",

}

A Guanidine-Based Synthetic Compound Suppresses Angiogenesis via Inhibition of Acid Ceramidase. / Cho, Sung Min; Lee, Hyung Keun; Liu, Qing; Wang, Ming Wei; Kwon, Ho Jeong.

In: ACS Chemical Biology, Vol. 14, No. 1, 18.01.2019, p. 11-19.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Guanidine-Based Synthetic Compound Suppresses Angiogenesis via Inhibition of Acid Ceramidase

AU - Cho, Sung Min

AU - Lee, Hyung Keun

AU - Liu, Qing

AU - Wang, Ming Wei

AU - Kwon, Ho Jeong

PY - 2019/1/18

Y1 - 2019/1/18

N2 - Angiogenesis generates new blood vessels from pre-existing vessels. Tumors induce the formation of new blood vessels to ensure sufficient oxygen and nutrients for their growth. Normally, angiogenesis is induced by various pro-angiogenesis factors, including vascular endothelial growth factor (VEGF). Inhibition of VEGF is a promising approach to cancer treatment. A guanidine-based synthetic compound, E2, was identified as a potent hit from 68 guanidine-based derivatives by screening for angiogenesis inhibitors showing antiproliferative activity in human umbilical vein endothelial cells (HUVECs). To explore the mode of action of E2, target proteins were investigated using phage display biopanning, and acid ceramidase 1 (ASAH1) was identified as an E2-binding protein. Drug affinity responsive target stability (DARTS) and ASAH1 activity assays revealed the direct binding of E2 to ASAH1. Moreover, siRNA knockdown of ASAH1 demonstrated its role as an angiogenesis factor. Consequently, E2 inhibited chemoinvasion and tube formation of HUVECs in a dose-dependent manner. E2 also potently suppressed neo-vascularization of chorioallantoic membranes in vivo. Collectively, these data suggest that E2 is a novel angiogenesis inhibitor and ASAH1 is proposed to be a new antiangiogenesis target.

AB - Angiogenesis generates new blood vessels from pre-existing vessels. Tumors induce the formation of new blood vessels to ensure sufficient oxygen and nutrients for their growth. Normally, angiogenesis is induced by various pro-angiogenesis factors, including vascular endothelial growth factor (VEGF). Inhibition of VEGF is a promising approach to cancer treatment. A guanidine-based synthetic compound, E2, was identified as a potent hit from 68 guanidine-based derivatives by screening for angiogenesis inhibitors showing antiproliferative activity in human umbilical vein endothelial cells (HUVECs). To explore the mode of action of E2, target proteins were investigated using phage display biopanning, and acid ceramidase 1 (ASAH1) was identified as an E2-binding protein. Drug affinity responsive target stability (DARTS) and ASAH1 activity assays revealed the direct binding of E2 to ASAH1. Moreover, siRNA knockdown of ASAH1 demonstrated its role as an angiogenesis factor. Consequently, E2 inhibited chemoinvasion and tube formation of HUVECs in a dose-dependent manner. E2 also potently suppressed neo-vascularization of chorioallantoic membranes in vivo. Collectively, these data suggest that E2 is a novel angiogenesis inhibitor and ASAH1 is proposed to be a new antiangiogenesis target.

UR - http://www.scopus.com/inward/record.url?scp=85060134794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060134794&partnerID=8YFLogxK

U2 - 10.1021/acschembio.8b00558

DO - 10.1021/acschembio.8b00558

M3 - Article

VL - 14

SP - 11

EP - 19

JO - ACS Chemical Biology

JF - ACS Chemical Biology

SN - 1554-8929

IS - 1

ER -